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Abstract 
SRI41716A is the first selective and orally active antagonist of the brain cannabinoid receptor. This compound displays nanomolar affinity for 
the central cannabinoid receptor but is not active on the peripheral cannabinoid receptor. In vitro, SR141716A antagonises the inhibitory effects 
of cannabinoid receptor agonists on both mouse vas deferens contractions and adenylyl cyclase activity in rat brain membranes. After intraperitoneal 
or oral administration SRl41716A antagonises classical pharmacological and behavioural effects of cannabinoid receptor agonists. This compound 
should prove to be a powerful tool for investigating the in vivo functions of the anandamidelcannabinoid system. 
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1. Introduction 
The behavioural and pharmacological actions of the 
active constituents of marijuana have been intensively 
studied and well documented [l]. Recent reports have 
shown that the major psychoactive component of canna- 
bis, d9-THC, as well as the putative endogenous ligand 
for the cannabinoid receptor, anandamide [2] mediate 
their pharmacological effects through a specific G pro- 
tein-coupled receptor [3] which has been recently cloned 
both in rat [4] and human [5]. This receptor, designated 
CBl, is found in brain but also in lower abundance in 
some peripheral tissues [6,7]. Recently a novel type of 
cannabinoid receptor, designated CB2, that seems to be 
only expressed at the periphery and involved in cannabi- 
noid-mediated immune modulation, has been described 
[8]. In the last few years, a number of potent synthetic 
cannabinoid agonists have been developed [9,10,11]. A 
putative cannabinoid receptor antagonist has been re- 
cently claimed [12], but no evidence has been found sup- 
porting in vivo antagonist effects of this compound [13]. 
Therefore, the search for more potent antagonists of the 
cannabinoid receptor was warranted. Based on both 
binding and functional data, this paper introduces 
SR141716A [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4- 
dichlorophenyl)-4-methyl- 1 H-pyrazole-3-carboxamidehy- 
*Corresponding author. Fax: (33) 67 10 67 67. 
Abbreviations: Tris, Tris-[hydroxymethyllaminomethane, d9-THC, 
tetrahydrocannabinol; i.p., intraperitoneal; p.o., per OS; i.v., intrave- 
nous; CHO, Chinese hamster ovary. 
drochloride] (Fig. l), as a novel, highly potent, selective 
and orally active antagonist for CB 1. This discovery pro- 
vides a new tool to better understand the mechanisms by 
which marijuana produces its pharmacological effects 
and to develop potential therapeutic agents. 
2. Materials and methods 
2.1. Materials 
Bovine serum albumin was from Boehringer. Forskolin was from 
Sigma. Polyethylenenimine was purchased from Serva. Biofluor liquid 
scintillant and [7H]CP 55,940 (111.9 Ci/mmol) were purchased from 
New England Nuclear Corp. A CAMP kit was from Amersham. Di- 
methyl sulfoxide was purchased from Prolabo. Tris was purchased from 
Merck-Clevenot. CP 55,940 {[la,2-(R)-5-(l,l-dimethylheptyl)-2-[5-hy- 
droxy-2-(3-hydroxypropyl)cyclohexyl]-phenol} was generously pro- 
vided by Pfizer. WIN 55212-2 {R-(+)-(2,3-dihydro-5-methyl-3-[(4- 
morpholinyl}methyl]pyrol [1,2,3-de]-1,4-benzoxazin-6-yl)(l-naphthal- 
enyl)methanone monomethanesulfonate} was purchased from RBI. 
SR141716A {N-@iperidin-l-yl)-5-(4-chlorophenyl)-l-(2,4-dichlorophe- 
nyl)-4-methyl-lH-pyrazole-3-carboxamide hydrochloride (Fig. I) and 
anandamide {arachidonylethanolamide}were synthesised at Sanofi Re- 
cherche. Drugs were dissolved either in ethanol (anandamide, dy-THC) 
or dimethyl sulfoxide (CP55,940, WIN55212-2, SR141716A). The con- 
centration of solvent in assays never exceeded 0.1% (v/v). This final 
concentration was without effect on radioligand binding. Male Spra- 
gueeDawley rats (18s-220 g) were obtained from Charles River 
(France) and used for in vitro binding studies. Male Swiss mice (30-35 
g) were obtained from CERJ, Le Genet St. Isle (France) and used for 
isolated vasa deferentia preparations. Male mice (Ofl, 25-27 g) and rdtS 
(Ofa, 120-140 g) were obtained from Iffa Credo (France) and used for 
psycopharmacological tests. 
2.2. Membrane preparations 
Rat membranes were prepared from the brain, minus the cerebellum 
or the substantia nigra as in [14] or from the spleen as in [6]. They were 
suspended in 20 mM HEPES (pH 7.4) at a final protein concentration 
of 10 mg/ml. Membranes isolated from CHO cells expressing either 
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CBl, obtained from a frontal cortex cDNA library, or CB2 isolated 
from a monocytic cell line U937 cDNA library [15,16], were prepared 
56 h after transfection as in [17]. They were suspended in 50 mM 
Tris-HCl (pH 7.4) at a final protein concentration of 0.3 mg/ml. Protein 
concentration was determined as in [18] and membranes were stored at 
-80°C until use. 
2.3. Binding experiments 
For in vitro binding assays membranes (7-50 pg) were incubated at 
30” C with [‘H]CP 55,940 in 1 ml of buffer A (50 mM Tris-HCl, pH 
7.7) for 1 h. A rapid filtration technique using Whatman GF/C filters 
(pre-treated with polyethylenenimine 0.5% (w/v)) and a 48-well filtra- 
tion apparatus (Brandel) was used to harvest and rinse labelled mem- 
branes (3 x with 5 ml of cold buffer A containing 0.25% bovine serum 
albumin). The radioactivity bound to the filters was counted with 4 ml 
of biofluor liquid scintillant. Non-specific binding was determined in 
the presence of 1 ,uM CP 55,940. Data from equilibrium binding (&, 
B,,,) and competition experiments (IC,,, ED,,) were analyzed using a 
non-linear least-squares method on a Compak Desk Pro 4/66i com- 
puter. All experiments were performed in duplicate and results were 
confirmed in at least three independent experiments. 
For selectivity, binding assays were carried out using standard proto- 
cols. 
2.4. Isolated mouse vasa deferentia preparations 
Assays were performed as previously described [2,19]. Drugs were 
added once the contractile responses to electrical stimulation were re- 
producible. Preparations were exposed to cumulative increasing con- 
centrations of CP 55,940 or anandamide to obtain concentration-re- 
sponse curves either in the absence (control) or in the presence of 
SR141716A added at a fixed concentration 60 min and 120 min before 
the first concentration of CP 55,940 and anandamide, respectively. 
2.5. Adenylyl eyclase assays 
Basal and forskolin-stimulated adenylyl cyclase activities were car- 
ried out in rat substantia nigra membranes (25pg) as in [20] and in CHO 
cells expressing CBl or CB2 as in [21]. The CAMP concentration was 
determined by radioimmunoassays. 
2.6. Drug preparation and administration 
For in vivo experiments, SR141716A was dissolved in two drops of 
Tween 80, diluted in distilled water and administered i.p. (30 min) or 
p.o. (1 h) in a volume of 20 ml/kg to male mice or 5 ml/kg to male rats 
before the i.v. injection of WIN55212-2 (dissolved in two drops of 
Tween 80 and diluted in saline solution). Doses are expressed as the salt. 
2.7. Psychopharmacological tests, in rodents 
Behavioural responses induced by WIN55212-2 were assessed either 
15 min (tail flick [22], ring-immobility [23]) or 30 min (hypothermia [24]) 
after the administration of SR141716A. Pop corn effects in mice and 
barrel rotations in rats were analyzed as described in [25] and [26], 
respectively. 
3. Results and discussion 
3.1. Interaction of SR141716A with brain cannabinoid 
receptors in vitro 
As shown in Fig. 2A, known cannabinoid drugs and 
SRI41 7 16A displaced in a concentration-dependent 
manner [3H]-CP55,940 specifically bound to its high af- 
finity receptor in rat brain synaptosomal membranes. 
The concentration-response curves gave Ki values of 
1.37 f 0.43, 9.94 f 1.04, 35.30 + 5.05 and 1.98 & 0.36 
nM (n = 4) for CP55,940, WIN55212-2, d9THC and 
SR141716A, respectively. In contrast, as shown in Fig. 
2B, SR141716A displayed no affinity for the cannabi- 
noid receptor expressed in rat spleen, except at a very 
high concentration (38.6 +_ 2.5% inhibition at 10m6 M, 
n = 3), whereas CP55,940, WIN55212-2 and d9-THC 
acted as potent displacers of these sites (Ki = 1.37 + 0.38 
nM, n = 8, 16.2 f 5.5 nM, n = 4 and 3.90 + 0.95 nM, 
n = 5, respectively). Furthermore, in membranes isolated 
from CHO cells expressing human CBl, SR141716A was 
a potent inhibitor of [3H]-CP55,940 binding sites with a 
Ki value of 5.6 f 0.5 nM (n = 4), whereas SR141716A 
displayed only a very low affinity for membranes from 
CHO cells expressing human CB2 (38.7 + 0.8% inhibi- 
tion at 10V6 M, n = 4). These results show that 
SR141716A is selectif for CBl versus CB2 and interacts 
with the cloned human cannabinoid receptor. 
In the presence of 2 nM SR141716A, [3H]CP55,940 
saturation binding experiments performed in rat brain 
membranes howed a significant increase (P < 0.05) in 
the dissociation constant (&) of [3H]CP55,940 
(SR141716A, & = 0.23 f 0.04 nM versus control, 
Kd = 0.09 4 0.01 nM, n = 3) with no significant change 
(P > 0.05) in the maximum number of receptors (B,,,) 
of [3H]CP55,940 (SR141716A, B,,, = 0.94 f 0.10 pmol/ 
mg of protein versus control, BmaX = 0.95 & 0.04 pmoY 
mg of protein). These results indicate that SR141716A 
is a competitive ligand for CBl. 
3.2. Receptor binding profile of SR141716A 
SR141716A had no affinity (IC,, > 1 ,uM) for any of 
the other types of receptors or channels investigated 
[histamine (H,, H,, H,), dopamine (D,, D2), adrenergic 
(a,, a2, B,, BJ, adenosine (A,, AZ), purinergic (PZY), opi- 
ate, neurotensin, cholecystokinin (A, B), benzodiazepine, 
sigma, tachykinin (NIL,, NK,, NK,), excitatory or inhib- 
itory amino acids (glycine, AMPA, kainate, NMDA, 
GABA,, GABA,), 5-hydroxytryptamine (5-HT,, 5-HT,, 
5-HT,) receptors and Cl-, Na+ (sitel, site2), Ca” (N, L) 
and K’ channels. These findings show that SR141716A 
is a very selective ligand for CBl. 
3.3. Cannabinoid receptor antagonism properties of 
SR141716A in vitro 
Cannabinoid agonists have been shown to inhibit neu- 
ronally stimulated smooth muscle contractions [19]. As 
Fig. 1. Structure of SR141716A. 
242 h4. Rinaldi-Carmona et al. IFEBS Letters 350 (1994) 240-244 
100 
90 
8 80 
WI 70 
j 6o 
50 
4 40 
& 30 
20 
10 
100 
90 
80 
70 
60 
50 
40 
30 
20 
10 
-11 -10 -9 -8 -7 -6 
Log concentration (M) 
Fig. 2. Inhibition of [SH]CP55,940 binding to rat brain (A) and spleen (B) membranes by various cannabinoid drugs and SR141716A. Binding assays 
were carried out at 30°C as described in section 2 using 0.1 nM [‘H]CP55,940 and increasing concentrations of CP 55,940 (A), WIN 55,212-2 (o), 
kTHC (m) and SR141716A (0). Data are from one experiment out of 3 performed in duplicate and are expressed as the percentage of specific binding 
in the absence of competitor. 
shown in Fig. 3, in the mouse vas deferens CP 55,940 and 
anandamide induced a concentration-dependent i hibi- 
tion of the twitch contractions with pD, values of 
8.41 + 0.03 and 7.8 f 0.04, respectively. SR141716A 
produced a concentration-dependent rightward and al- 
most parallel shift of the concentration-response curve 
for both compounds, showing that it behaved as a com- 
petitive antagonist versus the synthetic cannabinoid ag- 
onist CP55,940 and the putative endogenous ligand an- 
andamide with pA, values of 7.98 f 0.03 and 
8.17 + 0.06, respectively. 
Cannabinoid receptor activation has been shown to 
inhibit CAMP accumulation [20]. As previously de- 
scribed [12], the cannabinoid agonist WIN55212-2 in- 
hibited in a concentration-dependent manner 
(IC,, = 40.0 + 3.6 nM, n = 3) the forskolin-stimulated 
adenylyl cyclase activity in rat substantia nigra synap- 
tosomal preparations. A maximum inhibition of 
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Fig. 3. Cumulative concentration-response curves for CP 55,940 (A) or anandamide (B) on the amplitude of twitch contractions elicited by electrical 
field stimulation of the mouse vas deferens obtained in the absence (0) (control) and in the presence of SRl41716A at lOm8 M (B), 3 x 10m8 M (A) 
and lo-’ M (7). Assays were performed as described in section 2. Data are expressed as a percentage of control values after incubation with 
SR141716A. Each point is the mean value k S.E.M. of 6 determinations. 
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35.0 * 1.5% (n = 8) was observed at lo-’ M of 
WIN55212-2. SR141716A, which produced no signifi- 
cant effect on either basal or forskolin-stimulated ade- 
nylyl cyclase activity completely reversed the inhibition 
exerted by WIN55212-2 (10d5 M) with an IQ0 value of 
48.0 z!z 2.7 nM (n = 3). In CHO cells expressing either 
human CBl or CB2, CP55,940 exerted an inhibitory 
effect on the forskolin-stimulated adenylyl cyclase with 
I&, values of 1.27 + 0.37 nM (n = 3) and 2.51 * 0.25 
nM (n = 3), respectively. SR 14 17 16A which produced no 
effect by itself, completely antagonised the inhibition 
elicited by CP55,940 (3 x 10m9 M) in CHO cells express- 
ing CBl (I&, = 5.6 nM) but not in cells expressing CB2 
(I&, > 1 PM). Taken together, these in vitro results indi- 
cate that SR 1417 16A is a potent and selective antagonist 
of the brain cannabinoid receptor. 
3.4. In vivo antagonism of SR141716A at central 
cannabinoid receptors 
The in vivo antagonism of SR1417 16A for the brain 
cannabinoid receptors was investigated in several animal 
models classically used to study cannabinoid drug ef- 
fects. As previously described [13], WIN55212-2 injected 
i.v. (0.8 mg/kg) produced hypothermia (-3.5”C), ring 
immobility (85% immobility) and increased tail-flick la- 
tency (12 s) in mice. In addition, WIN55212-2 (1.6 mg/ 
kg, i.v.) induced ‘pop corn’ effects in mice, hypothermia 
(-3°C) and barrel rotations in rats. As shown in Table 
1, SR141716A administered i.p. or p.o. potently and 
dose-dependently antagonised the responses elicited by 
WIN55212-2 in all evaluation tests. Interestingly, 
SR1417 16A alone failed to produce any effect on these 
pharmacological and behavioural models, suggesting 
that control of body temperature as well as behaviour 
responses to noxious heat are not under the tonic influ- 
ence of an endogenous CBl ligand. Furthermore, 
SR1417 16A administered i.p. did not antagonise the hy- 
pothermia produced by reserpine (2 mg/kg, ip.), oxot- 
remorine (0.1 mg!kg, p.o.) or apomorphine (1 mg/kg, 
subcutaneous) in mice. As shown in Fig. 4, the reversal 
by SR141716A of WIN55212-2-induced hypothermia 
Table 1 
Antagonism by SR141716A of pharmacological and behavioural re- 
sponses induced by WIN55212-2, in rodents 
Test Species WIN55212-2 EDSo of SR141716A 
(mg/kg, i.v.) (m&g [95% CL]) 
Hypothermia mouSe 0.8 
rat 1.6 
Antinociception mouse 0.8 
Ring-immobility mouse 0.8 
Popcorn effect mouse 1.6 
Barrel rotations rat 1.6 
0.28 [0.12X).65], i.p. 
0.38 [0.21-0.71], p.o. 
0.11 [0.03-0.38], i.p. 
0.15 [0.034.36], p.o. 
1.62 [0.24-10.91, i.p. 
1.70 [0.70-4.30], i.p. 
0.62 [0.46-0.84], i.p. 
0.54 [0.31-0.90], i.p. 
38 
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Fig. 4. Time course of the antagonism of WIN55212-2 induced hypoth- 
ermia by SR141716A, in mice. Groups of mice (10 per group) were 
administered orally with vehicle (o), 1 (*), 3 (0) or 10 m&g (A) of 
SR141716A. At different times after the administration of SR141716A 
the effect of WIN55212-2 injected intravenously (0.8 mg/kg) on colonic 
temperature was evaluated. All data are the mean f S.E.M. The Stu- 
dent t-test was used to obtain a measure of significance between control 
and SR141716A treated groups (*P < 0.05, **P < 0.01). 
was time-dependent and significant for at least 18 h after 
administration at 3 mg/kg (p.0.). These results show that 
SR141716A is a functional antagonist of the brain can- 
nabinoid receptor (CBl) with good oral bioavailability 
and a long duration of action. 
4. Conclusion 
In this report we describe for the first time a potent, 
selective and orally effective cannabinoid receptor antag- 
onist, SR141716A, that has a lOOO-fold higher affinity 
for the CB 1 receptor than for the recently described CB2 
receptor. Functional studies in vitro and in vivo show 
that SR1417 16A is able to antagonise the pharmacologi- 
cal effects, involving CBl, induced by both the known 
cannabinoid receptor agonists and the putative en- 
dogenous receptor ligand anandamide. Thus 
SR141716A may be considered as a useful tool to eluci- 
date the respective physiological or pathophysiological 
roles of central (CBl) versus peripheral (CB2) cannabi- 
noid receptors. 
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